Table 1.

Population, Intervention, Comparison, Outcome, and Setting (PICOS)

Item	Search Details
Population
Disease	Neovascular age-related macular degeneration
Intervention
Anti-VEGF therapy	Aflibercept, ranibizumab, bevacizumab, brolucizumab, abicipar used in patients with SRF and/or IRF at defined time points
Comparison
Anti-VEGF therapy	Aflibercept, ranibizumab, bevacizumab, brolucizumab, abicipar used in patients with no SRF and/or IRF at defined time points
Outcome
Primary: Functional outcomes at Year 1	Visual acuity, OCT data, CNV type (1–3 or PCV), fibrosis, RPE atrophy, macular atrophy, RPE detachment, vascular proliferation, treatment burden (number of injections and clinic visits), patient quality of life, uveitis, and safety
Secondary: Functional outcomes at other time points, morphologic outcomes, treatment burden, and safety
Setting
Study design	Randomized and observational studies

CNV, choroidal neovascularization; IRF, intraretinal fluid; OCT, optical coherence tomography; PCV, polypoidal choroidal vasculopathy; RPE, retinal pigment epithelium; SRF, subretinal fluid; VEGF, vascular endothelial growth factor.